Ignite Creation Date:
2024-05-05 @ 4:53 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00334581
Status:
COMPLETED
Last Update Posted:
2009-09-15
First Post:
2006-06-07
Brief Title:
Irbesartan in Chinese Hypertensive Diabetics With Microalbuminuria
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
A Study of Irbesartan 150mg Verses 300mg in Chinese Hypertensive Patients With Diabetes and Microalbuminuria
Status:
COMPLETED
Status Verified Date:
2009-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Primary objective
To determine if irbesartan 300mg is better than 150mg in protecting the kidneys in hypertensive patients with diabetes and microalbuminuria
Secondary objectives
To determine how well irbesartan 300mg is tolerated versus 150mg
To determine the percentage of patients reaching the blood pressure target of 13080 mmHg
To determine if irbesartan 300mg is better than 150mg in protecting the kidneys in hypertensive patients with diabetes and microalbuminuria
Secondary objectives
To determine how well irbesartan 300mg is tolerated versus 150mg
To determine the percentage of patients reaching the blood pressure target of 13080 mmHg
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None